As of close of business last night, Health Catalyst Inc’s stock clocked out at $6.58, down -1.35% from its previous closing price of $6.67. In other words, the price has decreased by -$0.09 from its previous closing price. On the day, 676692 shares were traded. HCAT stock price reached its highest trading level at $6.74 during the session, while it also had its lowest trading level at $6.52.
Ratios:
To gain a deeper understanding of HCAT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.39 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.67.
On January 03, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $14.
JP Morgan Upgraded its Neutral to Overweight on December 13, 2023, whereas the target price for the stock was revised from $14 to $11.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 15 ’24 when Llewelyn Linda sold 2,005 shares for $7.80 per share. The transaction valued at 15,648 led to the insider holds 128,231 shares of the business.
Burton Daniel D. bought 26,200 shares of HCAT for $204,525 on Feb 27 ’24. The Chief Executive Officer now owns 1,172,623 shares after completing the transaction at $7.81 per share. On Feb 15 ’24, another insider, Llewelyn Linda, who serves as the Chief People Officer of the company, sold 3,262 shares for $9.77 each. As a result, the insider received 31,855 and left with 64,786 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 385.34M and an Enterprise Value of 316.68M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.30 while its Price-to-Book (P/B) ratio in mrq is 1.05. Its current Enterprise Value per Revenue stands at 1.07 whereas that against EBITDA is -4.64.
Stock Price History:
Over the past 52 weeks, HCAT has reached a high of $14.37, while it has fallen to a 52-week low of $6.60. The 50-Day Moving Average of the stock is 8.64, while the 200-Day Moving Average is calculated to be 9.77.
Shares Statistics:
It appears that HCAT traded 614.26K shares on average per day over the past three months and 501.08k shares per day over the past ten days. A total of 58.30M shares are outstanding, with a floating share count of 55.71M. Insiders hold about 4.87% of the company’s shares, while institutions hold 86.86% stake in the company. Shares short for HCAT as of Mar 15, 2024 were 1.82M with a Short Ratio of 2.97, compared to 1.43M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.11% and a Short% of Float of 3.55%.
Earnings Estimates
As of right now, 14 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.03 for the current quarter, with a high estimate of $0.06 and a low estimate of -$0.06, while EPS last year was $0.05. The consensus estimate for the next quarter is $0.08, with high estimates of $0.12 and low estimates of $0.01.
Analysts are recommending an EPS of between $0.45 and -$0.01 for the fiscal current year, implying an average EPS of $0.32. EPS for the following year is $0.5, with 15 analysts recommending between $0.65 and $0.35.
Revenue Estimates
In the current quarter, 16 analysts expect revenue to total $75.08M. It ranges from a high estimate of $79.6M to a low estimate of $74.05M. As of the current estimate, Health Catalyst Inc’s year-ago sales were $71.24M, an estimated increase of 5.40% from the year-ago figure.
A total of 17 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $331M, while the lowest revenue estimate was $306.03M, resulting in an average revenue estimate of $309.89M. In the same quarter a year ago, actual revenue was $295.94M, up 4.70% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $345.24M in the next fiscal year. The high estimate is $353M and the low estimate is $337.8M. The average revenue growth estimate for next year is up 11.40% from the average revenue estimate for this year.
